Maternal serum S100 protein in normal and Down syndrome pregnancies
β Scribed by H. D. Abraha; P. L. Noble; K. H. Nicolaides; R. A. Sherwood
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 119 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0197-3851
No coin nor oath required. For personal study only.
β¦ Synopsis
Protein S100 is a low molecular weight (10-12 kD) calcium-binding protein the beta subunit of which is coded for at the 22.2-22.3 region of the long arm of chromosome 21. This region has also been shown to be responsible for the phenotypic expression of Down syndrome. Previous studies demonstrated increased immunoreactivity to protein S100 in brain tissue from adults with Down syndrome. We have previously observed a higher concentration of S100 protein in the fetal blood of trisomy 21 fetuses compared with normal subjects. The aim of this study was therefore to investigate the use of measuring S100 protein concentration in maternal blood for Down syndrome screening.
Maternal blood was taken at the time of chorionic villus sampling or cordocentesis (11-38 weeks' gestation) for fetal karyotyping. Protein S100 was measured by a two-site immunoradiometric assay (S-100 IRMA, Sangtec). There was no significant difference in the concentration of maternal S100 protein between normal and trisomy 21 pregnancies (p<0.10). Moreover, there was no significant association between maternal serum S100 protein concentration and gestational age (r s =0.27, p=0.07), maternal age (r s = 0.17, p=0.7) or maternal weight (r s = 0.013, p=0.9).
This study shows that measurement of maternal serum S100 protein concentration does not appear to have a value in Down syndrome screening.
π SIMILAR VOLUMES
To assess the influence of in vitro fertilization (IVF) on maternal serum human chorionic gonadotrophin (hCG) and alpha-fetoprotein (AFP), the maternal serum hCG and AFP values were studied in 67 IVF pregnancies and compared with the results of a control group of 4732 spontaneously conceiving patien
Several previous studies have suggested that maternal smoking is associated with a decreased incidence of trisomy 21. By using the Swedish health registries, 1,321 infants with Down's syndrome (DS) were selected among 1,117,021 infants born in 1983-1993 with known smoking exposure in early pregnancy
Inhibin A is now an established second-trimester maternal serum marker of Down syndrome. Since activin A has a common -subunit to inhibin A we evaluated this substance and its binding protein, follistatin, as potential markers. We studied 30 affected and 199 unaffected pregnancies at 13-16 weeks' ge
## Abstract Maternal serum pregnancy specific betaβ1 glycoprotein (SPβ1) levels in the second trimester may be predictive of Down syndrome (DS). An enzyme immunoassay was used to measure SPβ1 sera from 46 DS pregnancies and 117 normal control women matched for maternal age, gestational age, and len
The purpose of our study was to assess the influence of intra-uterine insemination (IUI) on the results of maternal serum Down syndrome screening. 43 women with IUI pregnancies and 4507 healthy women who conceived were studied. Ovulation in IUI pregnancies was induced by clomiphene and/or human meno